October 3, 2017 - Regulatory The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed
May 10, 2017 - Regulatory SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis
April 27, 2017 - Regulatory Utilisation of subscription options registered with Swedish Companies Registration Office
April 25, 2017 - Regulatory SynAct Pharma AB provides an update on the clinical development plan for AP1189
March 31, 2017 - Regulatory SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options
March 9, 2017 - Regulatory SynAct Pharma AB retains subscription rights for series TO 1subscription option
March 9, 2017 - Regulatory The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today
February 22, 2017 - Regulatory SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency
